Sunday night, newsmagazine 60 Minutes did a story on the threat represented by the unchecked container traffic at US ports. Under 5 percent are ever checked for anything.

We have been on biometric and explosives/narcotics/biological detector maker Sense Holdings for a while now.

Sense is at the forefront of this critical Homeland Security technology and as the public gets more and more aboard/concerned with who runs the ports, the threats apparent, etc, it likely bodes well for the Company’s robust, low cost detectors. I know I’d feel better if there were a slew of these handheld devices deployed at all North American ports.

Could well be a decent time to pick up the stock. The green line represents the best buying spot with support around 25 cents, a buy at .245 would be ideal, technically.

The multiple red lines represent resistance levels at .33, .31, .28 and .27. We consider this pattern a confluence area. Trading smallcap stocks is all about risk reward. I like our chances around .24 to .25 cents to see if it can gather momentum and break above that confluence area. If it does, watch out. A big rally would likely occur. Conversely, if it breaks below our .24 cents we’ll have to reassess.

Trade Safely

Biotech CEL-SCI hit 84 cents this am, a nice move from our 52 cent Alert price a couple of weeks ago. As noted then, we see some resistance here and a possible pullback, so traders might consider letting a bit go for a snappy 60 percent return since February 10th.

A core position should be held, but since the move has been profound and rapid, some profit taking might be warranted. Positions could be filled in on dips.

Long-term investors should maintain decent exposure, as we believe that the shares are destined to move higher. Here’s the chart:

Trade Safely.

As promised, we issued a Trading Alert on biotech CEL-SCI on Friday and the shares have been acting well.

This am, Midas Research out of Germany issued a research report. The only problem is that it’s in German and no english version is coming. The main thing is that their target for the shares is 2.35 euros or $2.80. You likely know the rest of the story. here’s the chart:

Would like to see the shares break out of the 50-60 cent range. Looks like that may be forthcoming. The details of the company are in our SmallCap Digest piece–link above.

This is our second rouind with this unique biotech. In late 2002 we introduced it to readers at 21 cents. The shares moved a few months later to almost $2. We think it is much further along, hopefully the FDA will grant it a Phase 3 trial for Multikine soon. It already has the go ahead for a Phase 3 from the highly respected Canadian equivalent of the FDA.

2006 looks an interesting year. the shares should be accumulated.

Trade Safely.

As promised in yesterday’s piece, I said I wanted your opinions on Google. Seems folks are ’searching’ for answers as this bad boy got pounded last week on tax rate worries. Would ya buy it? Should we sell it? Have the kahonies (sp?) to short it?

Love to know your thoughts on this phenomena…

As well, Friday after the close, SmallCap Digest is going to issue a Trading Alert on one of our previously followed companies. No hints, just that this one was an exceptional winner before and looks poised, in our opinion, to do it again. Or better.
Stay close to youyr email Friday Night or Saturday am… That way you’ll have lots of time to read about our pick and set out a strategy before the open Monday…